Project Grant R56DK148870
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $456K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Trustees of Tufts College (doing business as Tufts University School of Medicine) $735,358 on May 21, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to fund research on enteroendocrine cell reprogramming in metabolic disease. The project investigates mechanisms by which dietary obesity impairs gut enteroendocrine cells (EECs)—the sole source of circulating...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The General Hospital Corporation, doing business as Massachusetts General Hospital, $835,245 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award funds research to evaluate evidence-based strategies for preventing weight regain after discontinuation of high-dose glucagon-like peptide-1 (GLP-1) agonist therapy in adults with obesity history but...
- The National Heart, Lung, and Blood Institute awarded Trustees of Boston University (doing business as Boston University Medical Campus) $837,125 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on real-world effects of GLP-1 receptor agonists on cardiovascular-kidney-metabolic syndrome progression and lifetime costs in people with HIV and type 2 diabetes. The research addresses a critical gap in evidence-based guidance for type 2...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Joslin Diabetes Center, Inc. $868,285 on August 26, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate the mechanistic role of brown fat-derived lipid mediators and their analogs in metabolic health. The project, identified as R01DK146036, focuses on elucidating the signaling and molecular mechanisms through which the linoleic acid metabolite 12,13-DIHOME...
- The National Heart, Lung, and Blood Institute awarded Beth Israel Deaconess Medical Center, Inc. $1,725,948 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to generate real-world evidence on the effectiveness, safety, and value of glucagon-like peptide-1 receptor agonists (GLP-1RAs) for cardiovascular disease prevention among individuals with cardiovascular-kidney-metabolic syndrome. The project addresses a critical evidence gap: while randomized controlled...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Georgia State University Research Foundation Inc. $802,008 on June 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate interactions between glucagon-like peptide 1 receptor agonists and the hypothalamic-pituitary-adrenal axis as a strategy to improve weight loss outcomes and reduce adverse effects of obesity pharmacotherapies. The research targets...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded the University of Utah $143,550 on July 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate skeletal muscle mitochondrial efficiency in weight loss induced by glucagon-like peptide-1 receptor agonists such as semaglutide. The research examines how pharmacologically induced weight loss alters skeletal muscle mitochondrial oxidative phosphorylation...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The Regents of the University of California, San Francisco $203,244 on May 15, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to assess body composition changes in adolescents with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists. The study, led by principal investigator Sujatha Seetharaman, MD, will enroll 50 adolescents ages 12–17.99 years...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Adventhealth Orlando $151,816 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to conduct a real-world outcomes study of glucagon-like peptide-1 (GLP-1) medicines in type 1 diabetes patients. The project will assess weight loss, kidney disease progression, and major adverse events in type 1 diabetes patients treated with cardioprotective GLP-1 medicines...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The Johns Hopkins University $766,545 on July 10, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to evaluate cost offsets and spending patterns associated with glucagon-like-peptide-1 receptor agonist (GLP-1) therapy using real-world evidence methods. The research leverages Truveta, a national electronic health record database covering over 100 million patients...